Recent Updates
Recently added Catalysts
NTLA

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2020 Earnings and Company Updates

Key Takeaway: CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 fi

Full Press Release Details

CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo, will present its fourth quarter and full-year 2020 financial results and operational highlights in a conference call on February 25, 2021 at 8 a.m. ET.
U.S. callers should dial 1-833-316-0545 and international callers should dial 1-412-317-5726, approximately five minutes before the call.
All participants should ask to be connected to the Intellia Therapeutics conference call.
A replay of the call will be available through the Events and Presentations page of the Investors & Media section of the company’s website at www.intelliatx.com, beginning on February 25, 2021 at 12 p.m. ET.
About Intellia Therapeutics
Chief Financial Officer
Interim Head of External Affairs & Communications
Last updated: Feb 18, 2021